Derma Sciences Inc.04.27.16
Princeton, N.J.-based Derma Sciences Inc., a tissue regeneration company focused on advanced wound and burn care, announces that CGS Administrators LLC, a Medicare Administrative Contractor (MAC) for Parts A and B serving Kentucky and Ohio, has updated its local coverage determination (LCD) for cellular or tissue-based products (CTPs) of the lower extremity. As a result, the company’s Amnioexcel amniotic allograft membrane will be considered for reimbursement coverage with appropriate documentation of medical necessity for the treatment of chronic wounds of the lower extremity, including both diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). CGS is the sixth MAC to issue local coverage determinations for Amnioexcel.
The Amnioexcel membrane forms a protective covering over the wound while providing the key components found in human amnion including an intact extracellular matrix, cytokines and other growth factors. It integrates into the wound and helps provide the optimal environment to repair, reconstruct, and replace wound tissue.
“The addition of Amnioexcel by CGS follows the submission of peer-reviewed published clinical evidence, including our recently published randomized controlled trial results, that demonstrates improved patient outcomes,” said Barry Wolfenson, Group President, Advanced Wound Care at Derma Sciences. “We are very pleased to offer access to our amniotic tissue-based allografts to more than 2 million additional Medicare beneficiaries in CGS’ coverage area for the treatment of chronic wounds. We are focused on working with the remaining two MACs to provide Medicare beneficiaries in their jurisdictions with access to our novel clinically beneficial and cost-effective technology.”
“For more than two years we have been focused on executing our strategy to gain MAC coverage for Amnioexcel throughout the United States,” said Stephen T. Wills, interim executive chairman and principal executive officer of Derma Sciences. “The addition of CGS brings the total MACs covering Amnioexcel to six of the eight, with 86 percent of Medicare beneficiaries now eligible for coverage. The LCD from CGS is an important validation of our efforts and is an encouraging event for our sales organization as we expand the market for Amnioexcel.”
CGS serves more than 2 million Medicare Part A and B beneficiaries in Kentucky and Ohio. In addition to processing claims, each MAC is also responsible for issuing LCDs that specify which healthcare products and services are reimbursable through the Medicare Fee-for-Service program in the regions under its jurisdiction.
The Amnioexcel membrane forms a protective covering over the wound while providing the key components found in human amnion including an intact extracellular matrix, cytokines and other growth factors. It integrates into the wound and helps provide the optimal environment to repair, reconstruct, and replace wound tissue.
“The addition of Amnioexcel by CGS follows the submission of peer-reviewed published clinical evidence, including our recently published randomized controlled trial results, that demonstrates improved patient outcomes,” said Barry Wolfenson, Group President, Advanced Wound Care at Derma Sciences. “We are very pleased to offer access to our amniotic tissue-based allografts to more than 2 million additional Medicare beneficiaries in CGS’ coverage area for the treatment of chronic wounds. We are focused on working with the remaining two MACs to provide Medicare beneficiaries in their jurisdictions with access to our novel clinically beneficial and cost-effective technology.”
“For more than two years we have been focused on executing our strategy to gain MAC coverage for Amnioexcel throughout the United States,” said Stephen T. Wills, interim executive chairman and principal executive officer of Derma Sciences. “The addition of CGS brings the total MACs covering Amnioexcel to six of the eight, with 86 percent of Medicare beneficiaries now eligible for coverage. The LCD from CGS is an important validation of our efforts and is an encouraging event for our sales organization as we expand the market for Amnioexcel.”
CGS serves more than 2 million Medicare Part A and B beneficiaries in Kentucky and Ohio. In addition to processing claims, each MAC is also responsible for issuing LCDs that specify which healthcare products and services are reimbursable through the Medicare Fee-for-Service program in the regions under its jurisdiction.